Abstracts lated for paired observations between IBDQ and EQ-5D (n = 3320) and IBDQ and SF-6D (n = 3230). Least square regression models were investigated. RESULTS: The decile analysis demonstrated a consistent positive relationship with both utility scores. The correlations between the IBDQ and both the EQ-5D and SF-6D were statistically highly significant (p < 0.0001). The correlation coefficients for IBDQ with SF-6D and with EQ-5D were 0.85 and 0.76 respectively. A simple linear least square regression model of the relationship between EQ-5D and IBDQ explained 46% of the variance. A visual inspection of the residuals plot for the IBDQ/SF-6D model suggested some nonlinearity and an improved non-linear model explained 72% of the variance. The comparison of the two sets of values demonstrated the commonly observed ceiling effect for the EQ-5D and floor effect for the SF-6D and provided added face validity for the transformations. CONCLUSIONS: Given the strength, consistency, and predictable characteristics of the relationships, the algorithms appear to provide valuable and valid methods to estimate utilities from IBDQ scores in trials of Crohn's disease patients that have collected IBDQ scores but not utilities. The generalisability of this relationship to other groups of patients, for which the IBDQ is appropriate, should be investigated. 6 Schering-Plough, Sydney, NSW, Australia; 7 Fremantle Hospital, Fremantle, WA, Australia OBJECTIVES: To assess the relationship between (i) disease severity and quality of life and (ii) disease severity and health care resource use, in patients with Crohn's disease. METHODS: A prospective, cross sectional, pharmacoeconomics study was conducted in five centres in Australia, with patients recruited by specialist gastroenterologists. Each patient completed questionnaires comprising demographic, disease and health care utilisation questions, together with the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ) and the Assessment of Quality of Life (AQoL) multi-attribute utility instrument. Disease severity was assessed by the gastroenterologist, using the Crohn's Disease Activity Index (CDAI). RESULTS: Of the 154 patients recruited, 11 were excluded due to incomplete datasets or significant co-morbidity. The 143 patients analysed had a broad range of disease severity (CDAI 36-446), and included 23% with enterocutaneous fistulae. Stepwise regression analyses showed a negative relationship between disease severity and quality of life-irrespective of whether the latter was measured by the IBDQ (p < 0.0001) or the AQoL utility instrument (p < 0.0001). Age, gender and years since diagnosis did not significantly impact upon either of the quality of life outcomes. Health care resource utilisation increased with increasing CDAI (p < 0.001), with hospital admissions being the largest component cost. Even when patients with fistulae were excluded, the mean treatment cost for the most severe group (CDAI >= 220) was AUD$7852 annually, excluding medications. Finally, despite their young age (mean = 38 yrs), 27% of patients received a Government benefit; with the majority of these stating that this was primarily due to their Crohn's disease. CONCLUSIONS: More severe Crohn's disease is associated with poor quality of life for patients and places considerable burden upon health care and social welfare resources.
UB2 QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE
6 Schering-Plough, Sydney, NSW, Australia; 7 Fremantle Hospital, Fremantle, WA, Australia OBJECTIVES: To assess the relationship between (i) disease severity and quality of life and (ii) disease severity and health care resource use, in patients with Crohn's disease. METHODS: A prospective, cross sectional, pharmacoeconomics study was conducted in five centres in Australia, with patients recruited by specialist gastroenterologists. Each patient completed questionnaires comprising demographic, disease and health care utilisation questions, together with the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ) and the Assessment of Quality of Life (AQoL) multi-attribute utility instrument. Disease severity was assessed by the gastroenterologist, using the Crohn's Disease Activity Index (CDAI). RESULTS: Of the 154 patients recruited, 11 were excluded due to incomplete datasets or significant co-morbidity. The 143 patients analysed had a broad range of disease severity , and included 23% with enterocutaneous fistulae. Stepwise regression analyses showed a negative relationship between disease severity and quality of life-irrespective of whether the latter was measured by the IBDQ (p < 0.0001) or the AQoL utility instrument (p < 0.0001). Age, gender and years since diagnosis did not significantly impact upon either of the quality of life outcomes. Health care resource utilisation increased with increasing CDAI (p < 0.001), with hospital admissions being the largest component cost. Even when patients with fistulae were excluded, the mean treatment cost for the most severe group (CDAI >= 220) was AUD$7852 annually, excluding medications. Finally, despite their young age (mean = 38 yrs), 27% of patients received a Government benefit; with the majority of these stating that this was primarily due to their Crohn's disease. CONCLUSIONS: More severe Crohn's disease is associated with poor quality of life for patients and places considerable burden upon health care and social welfare resources.
UB3 A COMPARISON OF THE EQ-5D AND THE SF-6D IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
Brown MC Pfizer Limited, Sandwich, Kent, UK OBJECTIVES: To compare 2 preference-based measures of health, the EQ-5D and the SF-6D, in patients with pulmonary arterial hypertension (PAH). METHODS: PAH patients (n = 278) were administered the EQ-5D and SF-36 questionnaires in a sildenafil clinical study. Comparisons of the utility indices of the EQ-5D and the SF-36 (the SF-6D) were conducted using the study baseline data. Comparisons were made using the total group of patients, and a sub-group analysis by functional class was also conducted. Functional class was assessed using the WHO criteria for functional capacity and therapeutic class in patients with PAH; there are 4 WHO functional classes (FC I-IV), with higher classes associated with greater limitations in physical activity. RESULTS: In the total group of patients, the mean (SD) utility index scores of the EQ-5D and the SF-36 were similar ( . CONCLUSIONS: The EQ-5D and the SF-36 utility indices provide similar estimates for PAH patients overall. However, the agreement between the instruments is not consistent over the range of functional classes seen in PAH patients. (PsA) . With a number of novel treatments for PsA emerging, we examined the associations between clinical outcomes and health utilities for the purposes of economic evaluation. METHODS: Patient-level data from a pivotal, Phase III, randomized controlled trial of the fully human, anti-tumor necrosis factor monoclonal antibody, adalimumab, vs. placebo in the treatment of PsA were analyzed. All potentially relevant outcomes were included: patient-reported functional loss measured by the Health Assessment Questionnaire Disability Index (HAQ-DI), physician's assessment of psoriasis severity from the Psoriasis Area Severity Index (PASI), tender and swollen joint counts (TJC, SJC), age, sex, and disease duration. All measurements were collected for patients at baseline and Weeks 12 and 24. The health utility measurement, the SF-6D was derived from responses to the Short Form-36, a generic QoL questionnaire. Multiple linear regressions using generalized estimating equations were employed to identify significant predictors of the SF-6D. RESULTS: Mean baseline characteristics for 313 patients
UB4 DETERMINANTS OF HEALTH STATE UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS

